Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
| Autor: | Lombardi, Federico, Borggrefe, Martin, Ruzyllo, Witold, Lüderitz, Berndt |
|---|---|
| Zdroj: | European Heart Journal; Sep2006, Vol. 27 Issue 18, p2224-2231, 8p |
| Abstrakt: | Aims Treatment of atrial fibrillation remains a major clinical challenge owing to the limited efficacy and safety of anti-arrhythmic drugs, particularly in patients with structural heart disease. [ABSTRACT FROM PUBLISHER] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|